Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia
Sullerot et al.,
Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia,
GeroScience, doi:10.1007/s11357-021-00499-8
Retrospective 1,047 pneumonia patients in 5 COVID-19 geriatric units in France and Switzerland, significantly higher ICU admission and longer hospital stays with existing aspirin treatment. Numbers in this study appear to be inconsistent, for example the abstract says 147 of 301 aspirin patients died, shown as 34.3%, while Table 1 shows 104 of 301 (34.6%).
risk of death, 10.0% higher, RR 1.10, p = 0.52, treatment 101 of 301 (33.6%), control 224 of 746 (30.0%).
|
risk of ICU admission, 109.7% higher, RR 2.10, p = 0.007, treatment 22 of 301 (7.3%), control 26 of 746 (3.5%).
|
hospitalization time, 10.0% higher, relative time 1.10, p = 0.02, treatment 301, control 746.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sullerot et al., 7 Jan 2022, retrospective, propensity score weighting, multiple countries, peer-reviewed, 15 authors, study period 1 March, 2020 - 31 December, 2020.
Abstract: GeroScience
https://doi.org/10.1007/s11357-021-00499-8
ORIGINAL ARTICLE
Premorbid aspirin use is not associated with lower mortality
in older inpatients with SARS‑CoV‑2 pneumonia
Coralie Sullerot · Kevin Bouiller · Caroline Laborde · Marine Gilis · Amélie Fèvre · Arthur Hacquin ·
Patrick Manckoundia · Florence Hoefler · Messaline Bermejo · Aline Mendes · Christine Serratrice ·
Virginie Prendki · Stéphane Sanchez · Alain Putot · On behalf of ESGIE (European Society of Clinical
Microbiology, European Society of Clinical Microbiological and Infectious Diseases, Study Group for
Infections in the Elderly)
Received: 21 September 2021 / Accepted: 13 December 2021
© The Author(s), under exclusive licence to American Aging Association 2021
Abstract Platelet aggregation has been associated
with COVID-19 pathogenesis. In older patients hospitalized for SARS-CoV-2 pneumonia, we aimed to
investigate the association between aspirin use before
admission and the risk of in-hospital all-cause mortality. We performed a retrospective international cohort
study in five COVID-19 geriatric units in France
and Switzerland. Among 1,357 consecutive hospitalized patients aged 75 or older and testing positive
for SARS-CoV-2, we included 1,072 with radiologically confirmed pneumonia. To adjust for confounders, a propensity score for treatment was created, and
stabilized inverse probability of treatment weighting
(SIPTW) was applied. To assess the association
between aspirin use and in-hospital 30-day mortality,
SIPTW-adjusted Kaplan–Meier and Cox proportional
hazards regression analyses were performed. Of the
1047 patients with SARS-CoV-2 pneumonia and
median age 86 years, 301 (28.7%) were taking aspirin
treatment before admission. One hundred forty-seven
(34.3%) patients who had taken aspirin died in hospital within 1 month vs 118 patients (30.7%) without
aspirin. After SIPTW, aspirin treatment was not significantly associated with lower mortality (adjusted
hazard ratio: 1.10 [0.81–1.49], P = .52). Moreover,
patients on aspirin had a longer hospital stay and were
C. Sullerot · A. Hacquin · P. Manckoundia · A. Putot
Department of Geriatric Internal Medicine, Dijon
University Hospital, Dijon, France
A. Mendes
Division of Geriatrics, Geneva University Hospitals,
Geneva, Switzerland
K. Bouiller
Department of Infectious Diseases, Besançon University
Hospital, Besançon, France
C. Serratrice · V. Prendki
Division of Internal Medicine for the Aged, Geneva
University Hospitals, Geneva, Switzerland
C. Laborde · A. Fèvre
Department of Geriatric Internal Medicine, Nimes
University Hospital, Nimes, France
V. Prendki
Division of Infectious Diseases, Geneva University
Hospitals, Geneva, Switzerland
M. Gilis
Department of Geriatrics, Besançon University Hospital,
Besançon, France
S. Sanchez
Department of Clinical Research, Troyes Hospital, Troyes,
France
F. Hoefler · M. Bermejo
Department of Internal Medicine and Infectious Diseases,
Troyes Hospital, Troyes, France
A. Putot (*)
Service de Médecine Interne Gériatrie, Hôpital de
Champmaillot CHU, 21079 Dijon Cedex, France
e-mail: alain.putot@chu-dijon.fr
Vol.: (0123456789)
13
GeroScience
more frequently transferred to the intensive care unit.
In a large multicenter cohort of older inpatients with
SARS-CoV-2 pneumonia, aspirin use before admission did not appear to be associated with an improved
prognosis.
Keywords Aspirin · Antiplatelet · Pneumonia ·
Coronavirus · COVID-19 · Aged · Mortality
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit